ReviewJournal of diabetes research2020
The Threshold of the Severity of Diabetic Retinopathy below Which Intensive Glycemic Control Is Beneficial in Diabetic Patients: Estimation Using Data from Large Randomized Clinical Trials.
Review in Journal of diabetes research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Association between haemoglobin levels and the risk of diabetic retinopathy in adults with type 2 diabetes: a retrospective cohort study using the TriNetX network.Eye (London, England) · 2025Article
- The non-linear association between remnant cholesterol/high-density lipoprotein cholesterol ratio and diabetic retinopathy: a cross-sectional study in type 2 diabetic patients.Diabetology & metabolic syndrome · 2025Article
- Diagnostic value of choroidal vascular density in predicting the progression of diabetic retinopathy.Scientific reports · 2025Article
- MiR-9-3 hypermethylation is associated with stages of diabetic retinopathy.Journal of diabetes and metabolic disorders · 2024Article
- Prognostic factors for the development and progression of proliferative diabetic retinopathy in people with diabetic retinopathy.The Cochrane database of systematic reviews · 2023Review
- Recent developments on computer aided systems for diagnosis of diabetic retinopathy: a review.Multimedia tools and applications · 2023Article
- Natural History of Diabetic Retinopathy Through Retrospective Analysis in Type 2 Diabetic Patients-An Exploratory Study.Frontiers in public health · 2021Article
- Lysophosphatidylcholine Offsets the Protective Effects of Bone Marrow Mesenchymal Stem Cells on Inflammatory Response and Oxidative Stress Injury of Retinal Endothelial Cells via TLR4/NF-Journal of immunology research · 2021Article
- SERPINH1, Targeted by miR-29b, Modulated Proliferation and Migration of Human Retinal Endothelial Cells Under High Glucose Conditions.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Article
- Diabetic Retinopathy in the Aging Population: A Perspective of Pathogenesis and Treatment.Clinical interventions in aging · 2021Review
- Corrigendum to "The Threshold of the Severity of Diabetic Retinopathy below Which Intensive Glycemic Control Is Beneficial in Diabetic Patients: Estimation Using Data from Large Randomized Clinical Trials" by Yuqi Liu,Juan Li, Jinfang Ma, Nanwei Tong.Journal of diabetes research · 2020Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intensive glucose therapy can protect the retina of individuals with diabetes, but it is unknown if it provides the same protection to patients with different severity of diabetic retinopathy (DR). We finally included DR-related studies involving intensive glucose control with large sample size and long follow-up time, including five large and high-quality randomized clinical trials (RCTs): DCCT, UKPDS, ACCORD, AdRem, and VADT. With DCCT as a reference, we supposed a DR severity threshold that is verified by other RCTs then. We found that individuals who have DR lesions that are equivalent to or less severe than moderate NPDR achieve benefits for the retina by intensive glycemic control. However, these are realized only if the HbA1c in type 1 or type 2 diabetic patients is reduced at least by 0.8% versus the control group or it is reduced to <7% and >3 years of intensive glucose control is required. If the severity of DR lesions is worse than moderate NPDR, intensive glycemic control may not bring benefits.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.